Inactive Instrument

PCAS Stock

PCA

FR0000053514

PCAS specializes in developing, manufacturing, and marketing fine and specialty chemicals. Sales are distributed by family of products as follows: - synthesized pharmaceutical products (63.5%); - fine chemicals (36.5%): technical fluids and additives for the lubricant industry, chemical additive synthesis. The group also offers photochemical and new technology products (photosensitive materials, photo-initiators, and polymers for photography, reprography, and micro-electronics). At the end of 2022, the group had 7 production sites located in France (5), Canada and Finland. France accounts for 76% of net sales.

Employees

1,178

Sector

Pharmaceuticals

More about the company

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

09/02/24	Orapi: takeover bid reopens on February 12
02/02/24	Orapi: 3.15 million shares tendered to the takeover bid
22/12/23	Orapi: takeover bid opens on December 27
19/12/23	PCAS: 200 ME capital increase
03/11/23	PCAS: OPAS to start this Friday
25/10/23	PCAS Announces the Consolidated Net Sales Results for the Month of September 30, 2023	CI
17/10/23	Progyny, Inc. : Want to have a baby?
07/09/23	PCAS: Seqens launches minority share offer
06/09/23	PCAS SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI
28/07/23	PCAS SA Reports Consolidated Sales Results for the Period Ended June 30, 2023	CI
01/06/23	DIC Corporation completed the acquisition of PCAS Canada Inc. from PCAS SA.	CI
25/05/23	PCAS: sale of Canadian subsidiary confirmed
25/05/23	PCAS to Divest Canadian Arm to Japan's DIC	MT

25/10/23	PCAS: Net Sales as of September 30, 2023	GL
07/09/23	PCAS: RESULTS AS OF JUNE 30, 2023	GL
28/07/23	Pcas: Net sales as of June 30, 2023	GL
25/05/23	PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation	GL
03/05/23	PCAS enters into exclusive negotiations with DIC Corporation following receipt of an offer for the acquisition of its Canadian subsidiary, PCAS Canada Inc.	GL

09/02/24	Orapi : l'OPA réouvre le 12 février
02/02/24	Orapi : 3,15 millions d'actions apportées à l'OPA
05/01/24	Progyny, Inc.: ¿Quieres tener un bebé?
22/12/23	Orapi : l'OPA démarre le 27 décembre
19/12/23	PCAS : augmentation de capital de 200 ME

Manager	Title	Age	Since
Gildas Barreyre CEO	Chief Executive Officer	43	03/05/2025
Eric Moissenot DFI	Director of Finance/CFO	-	-
Gérard Guillamot CTO	Chief Tech/Sci/R&D Officer	-	01/03/1999

Director	Title	Age	Since
Jacqueline Lecourtier BRD	Director/Board Member	74	01/03/2014
Janine Cossy BRD	Director/Board Member	-	-

PCAS Stock

Stocks

PCA

FR0000053514

Pharmaceuticals

Latest news: PCAS

Press Releases: PCAS

News in other languages: PCAS

Managers and Directors: PCAS

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCAS	-.--%	-.--%	-	-	125M
ELI LILLY AND COMPANY	+0.04%	+3.34%	+53.32%	+100.52%	1,028B
JOHNSON & JOHNSON	-0.09%	+1.66%	+53.24%	+66.45%	651B
ABBVIE INC.	-0.02%	+2.66%	+18.65%	+71.97%	466B
ROCHE HOLDING AG	-1.22%	+3.66%	+34.59%	+38.81%	346B
NOVARTIS AG	-0.79%	+2.73%	+17.73%	+25.11%	266B
ASTRAZENECA PLC	+0.58%	+6.76%	+10.58%	+17.75%	259B
AMGEN INC.	+1.55%	+2.20%	+35.12%	+45.91%	208B
NOVO NORDISK A/S	+0.79%	+1.84%	-27.55%	-56.48%	191B
GILEAD SCIENCES, INC.	-0.52%	+4.45%	+31.57%	+98.11%	186B
Average	+0.03%	+3.26%	+25.25%	+45.35%	400.19B
Weighted average by Cap.	-0.04%	+3.09%	+34.84%	+61.60%